Results 61 to 70 of about 90,202 (264)

Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment

open access: yesAdvanced Science, EarlyView.
Combinations of small activating RNAs and small interfering RNAs were developed as personalized precision therapies that simultaneously activate tumor suppressors and silence oncogenes according to the molecular signatures of patient tumors. This combination strategy demonstrated superior anticancer efficacy, highlighting the promise of precision ...
Jing Wu   +18 more
wiley   +1 more source

Bioactive Peptides and Depsipeptides with Anticancer Potential: Sources from Marine Animals

open access: yesMarine Drugs, 2012
Biologically active compounds with different modes of action, such as, antiproliferative, antioxidant, antimicrotubule, have been isolated from marine sources, specifically algae and cyanobacteria.
Josafat-Marina Ezquerra-Brauer   +2 more
doaj   +1 more source

Hypomethylation of GNA15 Promotes Pancreatic Ductal Adenocarcinoma Progression and Macrophage M2 Polarization via STAT3‐CXCL8 Axis

open access: yesAdvanced Science, EarlyView.
A schematic model summarizing GNA15's mechanism in mediating macrophage M2 polarization and Gemcitabine resistance. ABSTRACT The complexity of pancreatic ductal adenocarcinoma (PDAC) progression, coupled with the lack of effective immunotherapy, underscores the imperative to deepen our understanding of its mechanisms and identify suitable immune ...
Weihui Guo   +8 more
wiley   +1 more source

Comparison of the Effects of Fucoidans on the Cell Viability of Tumor and Non-Tumor Cell Lines

open access: yesMarine Drugs, 2019
Fucoidans extracted from brown algae exert manifold biological activities paving the way for the development of numerous applications including treatments outside tumor therapy such as age-related macular degeneration or tissue engineering. In this study,
Kaya Saskia Bittkau   +6 more
doaj   +1 more source

Lenalidomide, an antiproliferative CLL drug

open access: yesBlood, 2014
In this issue of Blood , Fecteau et al show that lenalidomide inhibits proliferation of chronic lymphocytic leukemia (CLL) cells in vitro by targeting cereblon. Thus far, the clinical activity of this drug in CLL was believed to be mainly via the microenvironment.[1][1] ![Figure][2 ...
openaire   +3 more sources

Biophysical Characterization and Proteomic Analysis of Small Extracellular Vesicles Derived From Different Neural Cell Lines

open access: yesAdvanced NanoBiomed Research, EarlyView.
This study systematically compares small extracellular vesicles (sEVs) derived from four neural cell lines, revealing how cellular origin shapes vesicle biophysical properties and proteomic cargo. Distinct, lineage‐specific signatures linked to neuronal, astrocytic, and microglial functions are identified, highlighting the importance of cell source ...
Muhammad Waqas Salim   +4 more
wiley   +1 more source

A New Series of Cytotoxic Pyrazoline Derivatives as Potential Anticancer Agents that Induce Cell Cycle Arrest and Apoptosis

open access: yesMolecules, 2017
A new series of pyrazoline derivatives 1b–12b was designed, synthesized and evaluated for antiproliferative activity against three cancer cell lines (HepG-2, Hela and A549).
Hong Wang   +6 more
doaj   +1 more source

Bioactivities of endophytic Penicillia from Cupressaceae

open access: yesJournal of Crop Protection, 2013
The cypress family, Cupressaceae, has a global dispersion. Currently, endophytic microorganisms from plants are being investigated for their diversity and bioactivities.
Mahdieh Hosseini Moghaddam   +5 more
doaj  

Daphnoretin Induces Cell Cycle Arrest and Apoptosis in Human Osteosarcoma (HOS) Cells

open access: yesMolecules, 2012
In this study antiproliferation, cell cycle arrest and apoptosis induced by daphnoretin in human osteosarcoma (HOS) cells were investigated. Antiproliferative activity was measured with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide ...
Jinhai He, Shoubin Gu
doaj   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy